title: Drug development from the bench to the pharmacy: with special reference to dipeptidyl peptidase-4 inhibitor development.
abstract: The dipeptidyl peptidase-4 (DPP-4) inhibitor concept is an example of prospective drug design and development based upon a distinct endocrine hypothesis. The design of enzyme inhibitors is a pragmatic approach to drug design; being compatible with the identification and optimization of small molecules that have properties commensurate with oral administration, as well as acceptable drug metabolism, distribution and elimination characteristics. Glucagon-like peptide 1 (GLP-1), a hormone with a spectrum of favourable metabolic actions, including glucose-dependent stimulation of insulin and inhibition of glucagon secretion, provided the endocrine basis from which the idea of using DPP-4 inhibitors as anti-diabetic agents was developed. The origin of the DPP-4 inhibitor concept was inspired by the angiotensin-converting enzyme inhibitor approach, which succeeded in establishing a class of extensively used therapeutic agents for the treatment of cardiovascular disorders.
authors.affiliation: MSD A/S, Copenhagen V, Denmark.
authors.forename: R D
authors.initials: RD
authors.lastname: Carr
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004059:Diffusion of Innovation; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000627:therapeutic use*; D055808:Drug Discovery / Q000639:trends*; D005544:Forecasting; D052216:Glucagon-Like Peptide 1 / Q000037:antagonists & inhibitors; D006801:Humans; D012084:Renin-Angiotensin System / Q000187:drug effects
chemical_list: D054873:Dipeptidyl-Peptidase IV Inhibitors; D052216:Glucagon-Like Peptide 1